The impact of bortezomib based induction therapy vs no induction therapy on outcomes for light chain amyloidosis.
Study #: MM17-02
Study Status: Published
Bortezomib-based induction is associated with superior outcomes in light chain amyloidosis patients treated with autologous hematopoietic cell transplantation regardless of plasma cell burden.
Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, Kumar S, Qazilbash MH, Shah N, Hari P, D'Souza A.
Transplantation and Cellular Therapy. 2021, Mar 01: 27(3): 27(3):264.e1-264.e7. doi: 10.1016/j.jtct.2020.11.018. Epub 2020, Dec 21. PMCID:PMC8010222.
PMID: 33781533
Abstract